Purpose To explore the immune phenotype of peripheral blood mononuclear cells (PBMC) in patients with high-risk nonmuscle invasive bladder cancer (NMIBC). Methods We prospectively collected blood samples from patients with high-risk NMIBC treated at our institution. PBMC were analyzed by flow cytometry to determine the frequency of T cells and NK cells and the expression of immunoregulatory molecules (Tim-3, TIGIT and PD-1). PBMC from healthy donors (HD) were included for comparison, and associations with response to BCG were investigated. Results A total of 38 patients were included, 19 BCG responders and 19 BCG refractory. Compared to 16 PBMC from HD, the frequency of total NK cells was significantly higher in patients with NMIBC [15.2% (IQR: 11.4, 22.2) vs. 5.72% (IQR: 4.84, 9.79); p = 0.05], whereas the frequency of T cells was not statistically different. Both Tim-3 and TIGIT expressions were significantly higher in NMIBC compared to HD, particularly in NK cells [13.8% (11.0; 22.4) vs. 5.56% (4.20; 10.2) and 34.9% (18.9; 53.5) vs. 1.82% (0.63; 5.16), respectively; p < 0.001]. Overall, the expression of PD-1 in all cell types was low in both NMIBC patients and HD. The immune phenotype was not significantly different before and after initiation of BCG. However, the proportion of CD8 + T cells before BCG was significantly higher in responders. Conclusion The immune phenotype of PBMC from patients with high-risk NMIBC was significantly different from HD, regardless of the presence of disease or the initiation of BCG. Peripheral CD8 + T cells could play a role in response to BCG.
Introduction
Bladder cancer represents the 9th most common cause of cancer worldwide [1] . Of the 430,000 new cases diagnosed each year, around 75% of patients present with non-muscle invasive bladder cancer (NMIBC). These patients are usually treated with trans-urethral resection and in some cases with adjuvant intravesical instillations. However, NMIBC is associated with a high risk of recurrence and progression, justifying life-long routine monitoring and treatment [2, 3] . For this reason, bladder cancer represents one of the most expensive malignancies and is a major burden on healthcare expenditures [4] .
Systemic immune checkpoint blockade has recently changed the treatment landscape for advanced bladder cancer [5] . However, immunotherapy has been used to treat NMIBC for more than 30 years, and BCG is recommended in patients with intermediate and high-risk tumors, including all NMIBC tumors except primary, solitary, low grade, < 3 cm tumors with no CIS [3] . Although the mechanistic basis underlying the benefit of BCG for NMIBC remains partially unknown, studies in model systems suggest that BCG administered intravesically is processed by bladder cancer cells and normal urothelial, leading to antigen presentation and cytokine release. This allows immune cell recruitment to the tumor site, resulting in cytotoxicity to bladder cancer cells through various immune mechanisms, involving systemic activation of innate and adaptive immunity [6] .
Whether the immune response elicited as a result of NMIBC is restrained by immune checkpoints, similar to the spontaneous immune response in patients with more advanced bladder cancer has been poorly characterized. We sought to profile the expression of immune checkpoints including programmed death-1 (PD-1), T cell immunoglobulin and mucin protein-3 (Tim-3), and T cell immunoreceptor with Ig and ITIM domains (TIGIT), in peripheral blood mononuclear cells (PBMC) from patients with high-risk NMIBC treated with BCG, as well as from healthy donors (HD).
Materials and methods

Study samples
Within the context of an Institutional Review Boardapproved protocol, between January and September 2017, we prospectively collected blood samples from consecutive patients with a diagnosis of high-risk NMIBC (T1, high grade, CIS, or multiple recurrent large low-grade Ta). All patients were naïve of BCG therapy before the diagnosis of high-risk NMIBC, and the diagnosis was confirmed by a board-certified uropathologist. All pathology specimens were staged according to the TNM 2009 system of the International Union Against Cancer [7] and were graded according to the 2004 WHO classification [8] . Patients with high-grade or pT1 tumors underwent a second trans-urethral resection. All patients received at least a 6-week induction course of intravesical BCG instillations (ImmuCyst ® ) at our institution, according to guidelines [2, 3] . As this is a highly exploratory study, blood samples were collected at different time points, with the aim to investigate potential associations between PBMC immune phenotype and different clinical scenarios. Patients were followed with urinary cytology and cystoscopy every 3 months. A patient was considered BCG refractory if high-grade tumor appeared during BCG therapy or if CIS without concomitant papillary tumor was present at both 3 and 6 months [3] . For comparison purpose, we also included PBMC from healthy donors (HD) purchased from the New York blood center.
PBMC immune phenotyping
PBMC were obtained from whole blood after dilution in an equal volume of Dulbecco's phosphate-buffered saline (DPBS) and overlaid onto Ficoll-Paque Plus. Whole blood was centrifuged at 400G for 30 min at 20 °C with no brake.
Mononuclear cells from the interphase between plasma and Ficoll were harvested, washed twice in DPBS, and subjected to RBS lysis using ACK. After a final wash, the supernatant was discarded, and the pellet was resuspended in cold FACS buffer (DPBS containing 2% BSA and 2 mM EDTA).
PBMC were analyzed by fluorescence-activated cell sorting (FACS) to determine phenotype. In brief, cells were stained with fixable viability dye blue to ascertain viability (ThermoFisher), BV510-labeled anti-CD45 (BioLegend), APC-labeled anti-CD3 (BioLegend), A700-labeled anti-CD14 and anti-CD19 (BioLegend), APC-Cy7-labeled anti-CD16 (BioLegend), BV605-labeled anti-CD56 (BioLegend), BV786-labeled anti-CD4 (BD Bioscience), BB700-labeled anti-CD8a (BD Bioscience), BB515-labeled anti-Tim-3 (BD Biosciences), PE-labeled anti-TIGIT (eBio), and BV421-labeled anti-PD-1 (BioLegend). Cytometric analysis was performed on a BD LSR Fortessa X-20 and data were analyzed with FlowJo v10 (Treestar). For the analysis, cells were gated on live singlets followed by relevant lineage markers. Isotype control antibodies were included in each experiment to determine appropriate gating for Tim-3, TIGIT, and PD-1. 
Statistical analysis
Results
Characteristics of the population
We included 38 patients with high-risk NMIBC who received BCG, with a median age of 67 years [interquartile range (IQR): 58; 75] at the time of collection. Among the cohort, 74% were men and 72% were active or former smokers. Blood was collected during trans-urethral resection (second look or recurrence) for 28 patients and during clinic visits (BCG administration or surveillance) for 10 patients. At the time of collection, 26 patients had already received BCG induction and 12 patients were naïve of treatment.
Of note, 87% of the patients had a prior history of urothelial carcinoma. Twenty-five patients (66%) had a prior history of NMIBC. Seven patients were previously treated with intravesical Mitomycin, but none had received BCG following our inclusion criteria. Eight patients (21%) had a prior diagnosis of UTUC, of whom five underwent a radical nephroureterectomy and three had a distal ureterectomy with subsequent follow-up showing no recurrence.
The majority of the index lesions were high grade (95%). Eight patients had CIS only and two patients had pT1HG + CIS. Only two patients had recurrent multiple pTa LG tumors after intravesical Mitomycin. Overall, 28/38 patients had a second look. The pathological finding at the second look was pT0 in 18 patients, pTaHG in 6, pT1HG in 2, and CIS only in 2.
The median follow-up from the diagnosis of high-risk NMIBC was 11.6 months (IQR: 8.33; 15.3), with 19 patients (50%) presenting with either high-grade tumor during BCG therapy or CIS without concomitant papillary tumor at both 3 and 6 months. The remaining 19 patients had no evidence of disease and were considered BCG responders ( Table 1) . + , was similar between the two groups. Expression of both Tim-3 and TIGIT was significantly higher in PBMC from NMIBC patients compared to HD, particularly in NK Table 2) .
Comparison of the immune
In patients with NMIBC, 26 blood samples were collected after the first BCG instillation vs. 12 before initiation of BCG. To investigate if the difference in immune phenotypes between NMIBC patients and HD could be explained by changes induced by BCG therapy, we compared the two subgroups (blood collected before vs. after BCG initiation) and found no significant difference either in overall total NK and T cell frequency, or in checkpoint inhibitor expression (Supplementary Table 1 ).
Comparison of BCG-refractory vs. BCG-responsive patients
We were not able to demonstrate any significant difference between BCG-refractory and BCG-responsive patients for the different markers of interest. However, when comparing the trend from HD to BCG responders to BCG refractory, there was a significant p trend for increased Tim-3 expression in NK cells, CD4
+ and CD8 + T cells, as well as increased PD-1 expression in CD4 + and CD8 + T cells (Table 3 ). There was also a significant increase in the proportion of total NK cells from HD to BCG-refractory patients (Fig. 1) .
Interestingly, some patients had blood collected when there was no evidence of disease in the bladder. The immune phenotype was very similar with no significant differences between patients with and without tumor at the time of blood collection (Supplementary Table 2 ).
To identify potential biomarker predictive of response to BCG therapy, we compared phenotypes between BCGresponder and BCG-refractory patients for whom blood was collected before initiation of BCG. Although the number of samples was limited (seven responsive vs. five refractory patients), we found that the proportion of CD8 Table 3 ). 
Discussion
In this study, we aimed to explore the immune phenotype of PBMC in patients with high-risk NMIBC. We found significant differences compared to HD. Furthermore, we hypothesized that peripheral CD8 + T cells could play a role in response to BCG. The importance of the immune response to cancer has been known for more than a century, with the first use of bacterial vaccines for the treatment of cancer described at the end of the 19th century [9] . Furthermore, urologists have been using intravesical BCG as an immune therapy for several decades [10] . Until recently, little was known regarding regulation of the peripheral antitumor immune response, and most studies have focused on local immune responses within the tumor, particularly the role of tumor-infiltrating lymphocytes. However, PBMC from cancer patients may reveal evidence of pathology at distal sites that is either imprinted by tumor-residency followed by a return to circulation, or by tumor-derived mediators able to alter the phenotype of peripheral cells. In addition, because PBMC can be collected with much greater ease than tissue obtained during surgery, characterization may provide clinically relevant insights. Recent literature has shown a growing interest for circulating lymphocytes subsets, and the prognostic significance of neutrophil-to-lymphocyte ratio has been investigated in a variety of different individual tumors, including NMIBC [11] . Although it reflects inflammatory reaction and perhaps antitumor activity, this marker does not bring enough granularity to reflect the systemic modifications of the immune system.
In this study, we aimed to explore the immune landscape of PBMC in high-risk NMIBC. Despite limitations related to the exploratory nature of the study, we were able to generate several hypotheses. First, we found that the phenotype of PBMC from patients with NMIBC was significantly different from HD, regardless of the presence of disease at the time of collection or the initiation of the BCG therapy. This includes a higher proportion of total NK cells and higher expression of Tim-3, TIGIT, and PD-1 in most lymphocyte lineages. Recent experimental studies have demonstrated that a systemic response is required to induce tumor rejection, including higher levels of NK cells, activated B cells, and T cells [12] . Interestingly, we found that there was no difference in PBMC from patients with or without tumor at the time of blood collection, suggesting that the changes induced by NMIBC on the peripheral immune system remained longer than the disease itself. However, we were not able to demonstrate significant differences between BCG-refractory and BCG-resistant patients, although there was a trend towards higher Tim-3 expression by NK, CD4 + and CD8 + T cells, as well as PD-1 by CD4 + and CD8 + T cells for the patients who were resistant to BCG therapy.
Systemic activation of the immune system has been shown to be critical to induce effective anti-tumor activity, even for a therapy delivered locally [12] . However, tumors can subvert effective immunosurveillance by inducing expression of inhibitory immune checkpoint molecules on both tumor and immune cells [13] . Among these molecules, CTLA-4 and PD-1/PD-L1 were the most studied but there is significant interest in identifying additional inhibitory receptors expressed by NK and T cells, including Tim-3 and TIGIT. The development of monoclonal antibodies directed against PD-1/PD-L1 and their successes in the clinic have generated much interest for this pathway, as the interaction between PD-1 and its ligand can impair T cell survival and inhibit proliferation, cytokine secretion, and cytotoxic ability [14] . However, most of the studies focused on the prognostic/predictive value of PD-L1 expression in tumor tissue, both by tumor cells and tumor-infiltrating immune cells [15] . Our findings suggest that expression of PD-1 by PBMC remains low during NMIBC, and therefore may not represent a significant biomarker in the periphery in NMIBC.
TIGIT is also an inhibitory receptor recently discovered [16] . Activation of TIGIT on human NK cells results in decreased IFN-γ production, cytotoxic granule polarization, and NK cell cytotoxicity [17] . Furthermore, it regulates antitumor activity in CD8 + T cells [18] . Consequently, its high expression in PBMC of patients with NMIBC could reflect the systemic changes induced by the tumor.
Tim-3 is also a surface receptor expressed on NK cells, and CD4
+ and CD8 + cells. It is involved in NK, T cell, and myeloid cell exhaustion, and high Tim-3 expression has been found on CD4 + and CD8 + T cells in several cancers, including melanoma or renal cell carcinoma [19, 20] . Furthermore, high expression of Tim-3 was correlated with higher cancer stage in renal cell carcinoma, colorectal cancer, melanoma, head and neck cancer [20] [21] [22] , and predicted poor prognosis in melanoma [23] and lung adenocarcinoma [24] . In our study, there was a trend toward a higher expression of Tim-3 in NK cells, and CD4 + and CD8 + T cells in patients who were refractory to BCG compared to responders, suggesting a potential role in the aggressiveness of the disease. However, due to the small number of patients, further studies with longer follow-up are required to validate this hypothesis.
In NMIBC, despite several attempts to analyze the immune response in bladder tissue before and after BCG, there are currently no reliable biomarkers to predict the BCG-induced anti-tumor response efficacy [25] . This may partially be explained by the fact that the mechanisms of BCG effectiveness are still unclear. It is hypothesized that BCG induces not only direct cytotoxicity of tumor cells, but also innate and adaptive immune pathways [6] . 40% of patients receiving intravesical BCG have conversion of a previously negative tuberculin skin test, highlighting the principle that inflammatory immune responses in tissue can influence systemic/peripheral immunity [26] . Furthermore, after three instillations of BCG, there is increased BCGinduced killer cell activity in PBMC [27] . Although our study does not identify expression of Tim-3, TIGIT, or PD-1 by peripheral NK and T cells as predictive of response to BCG, serial blood collections before and after BCG therapy in patients with high-risk NMIBC could provide different information on an individual basis. Furthermore, functional studies could bring more refinement on the activation of the systemic immune system. Particularly, it would be interesting to compare the exhaustion of NK and T cells before and after BCG, and to evaluate the possibility to restore function with checkpoint inhibitors.
Identifying biomarkers of response to BCG therapy is critical in NMIBC, as patient refractory to this treatment is recommended for early radical cystectomy, and delay in surgery might lead to decreased disease-specific survival [28] . Although the numbers were limited, we found that a higher percentage of CD8 + T cells could be associated with response to BCG; however, its utility in clinical practice needs to be validated in a larger cohort. Similar findings were demonstrated in lung cancer patients treated with PD-1 targeted therapy [29] . Alternatives to BCG are currently under investigation and immune checkpoint inhibitors could potentially play a role for the treatment of NMIBC. There are currently several ongoing trials evaluating immune checkpoint inhibitors in BCG-unresponsive and relapsing NMIBC, as well as combination trials using BCG and immune checkpoint inhibitors in high-risk NMIBC [30] . In addition to these systemic treatments, other intravesical immunotherapies are being tested to reverse immune exhaustion. However, diagnostic testing that will predict response to treatment remains highly needed.
This study is limited by its sample size and the lack of functional studies to correlate with the immune phenotype. External validation is also required to evaluate its generalizability. Furthermore, the sample collection was performed at different time points which could introduce some bias, although we performed appropriate statistical analysis. We acknowledge that our study was mainly exploratory with the aim to generate hypotheses. Ongoing efforts are made to confirm these initial findings, in association with a better characterization of effector dysfunction on NK and T cells in bladder cancer. Despite these limitations, this is, to our knowledge, the first comprehensive analysis of the immune phenotype of PBMC in patients with high-risk NMIBC treated with BCG. We believe this is an area of interest with the potential to provide new tools to explore the immune response in NMIBC treated with BCG.
Conclusion
In this study, we found that immune phenotype of PBMC of patients with high-risk NMIBC was significantly different from HD, regardless of the presence of disease at the time of collection or the initiation of the BCG therapy. This includes a higher proportion of total NK and higher expression of Tim-3, TIGIT, and PD-1 in most lymphocytes lineages. Although we were not able to demonstrate significant differences between BCG-refractory and BCG-responsive patients, there was a trend towards a higher Tim-3 expression in NK cells, CD4 + and CD8 + T cells, as well as PD-1 in CD4 + and CD8 + T cells for the patients who were resistant to BCG therapy. Peripheral CD8 + T cells could play a role in response to BCG.
